Adrenoleukodystrophy (ALD) and Adrenomyeloneuropathy (AMN)

https://pmc.ncbi.nlm.nih.gov/articles/PMC11450743

Adrenoleukodystrophy (ALD) and adrenomyeloneuropathy (AMN) are X-linked genetic disorders with significant lifelong implications. ALD primarily affects men, but women can also develop debilitating symptoms, including progressive neuropathy and myelopathy, though adrenal insufficiency and cerebral demyelination are rare. Early identification of symptoms and establishment of care with a neurologist are essential for lifelong management and surveillance. Importantly, women with ALD should not be assumed asymptomatic, as many experience pain and mobility challenges that require intervention. Currently, disease-modifying therapies are limited to cerebral ALD (CALD) in children. Hematopoietic stem cell transplantation (HSCT) can halt disease progression in early-stage CALD, as of recently adult males may now be eligible with strict criteria in place. Gene therapy and PPAR-γ agonists like leriglitazone, are under investigation for AMN and CALD as novel therapies and while promising, these treatments are not yet approved for adults. Challenges in managing ALD/AMN include addressing emotional burdens, such as caregiver stress and genetic guilt, and improving access to specialised care. Women, often caregivers themselves, may deprioritise their own health, necessitating targeted mental health support. Future research is critical to understanding adult ALD/AMN, including biomarkers and advanced imaging techniques for improved risk stratification and treatment outcomes. Developing disease-specific interventions and expanding therapeutic options will enhance the quality of life for affected individuals. Additionally, neurologists must remain knowledgeable of emerging therapies and clinical trials to offer comprehensive, multidisciplinary care.